We serve Chemical Name:(S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine CAS:135616-36-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine
CAS.NO:135616-36-3
Synonyms:(S,S)-2,2′-[(1,2-cyclohexanediyl)bis(nitrilomethylidyne)]bis[4,6-di-tert-butylphenol];(S,S)-(-)-N,N’-BIS(3,5-DI-TERT-BUTYLSALICYLIDENE)-1,2-CYCLOHEXANEDIAMINE;(1S,2S)-N,N’-bis[(3,5-di-tert-butyl-2-hydroxyphenyl)methylene]-1,2-cyclohexanediamine;(S,S)-N,N’-bis(3,5-di-t-butylsalicylidene)-1,2-cyclohexanediamine;(1S,2S)-(+)-1,2-CYCLOHEXANEDIAMINO-N,N’-BIS(3,5-DI-T-BUTYLSALICYLIDENE);(1S,2S)-(+)-1,2-Cyclohexanediamino-N,N’-bis(3,5-di-tert-butylsalicylidene);(S,S)-JACOBSEN LIGAND;(1S,2S)-N,N’-bis(3′,5′-di-tert-butylsalicylidene)-cyclohexane-1,2-diimine;(S,S)-JACOBSEN’S LIGAND;Phenol, 2,2′-[(1S,2S)-1,2-cyclohexanediylbis[nitrilo(E)methylidyne]]bis[4,6-bis(1,1-dimethylethyl)-;MFCD00191801;(S,S)-(+)-N,N’-BIS(3,5-DI-T-BU-SALICYL.);(S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine;N,N’-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine;(1S,2S)-N,N′-bis-[3,5-di-tert-butylsalicylidene]-1,2-cyclohexanediamine;2,2′-{(1S,2S)-Cyclohexane-1,2-diylbis[nitrilo(E)methylylidene]}bis(4,6-di-tert-butylphenol);2,2′-{(1S,2S)-1,2-Cyclohexanediylbis[nitrilo(E)methylylidene]}bis[4,6-bis(2-methyl-2-propanyl)phenol];(S,S)-(+)-N,N′-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine
Molecular Formula:C36H54N2O2
Molecular Weight:546.826
HS Code:
Physical and Chemical Properties:
Melting point:203-206ºC(lit.)
Boiling point:615.2±55.0 °C at 760 mmHg
Density:1.0±0.1 g/cm3
Index of Refraction:1.536
PSA:65.18000
Exact Mass:546.418518
LogP:11.18
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like (S,S)-2,2′-[(1,2-cyclohexanediyl)bis(nitrilomethylidyne)]bis[4,6-di-tert-butylphenol] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(S,S)-(+)-N,N′-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(S,S)-JACOBSEN’S LIGAND Use and application,(1S,2S)-N,N’-bis[(3,5-di-tert-butyl-2-hydroxyphenyl)methylene]-1,2-cyclohexanediamine technical grade,usp/ep/jp grade.
Related News: Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry. (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine manufacturer The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine supplier The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo. (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine vendor The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine factory Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine supplier The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo. (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine vendor The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine factory Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities.
